ESMO WCGIC 2023 | Does neoadjuvant chemotherapy have a role in resectable pancreatic cancer?

Thomas Seufferlein, MD, PhD, Ulm University, Ulm, Germany, explains how neoadjuvant chemotherapy should not be currently conducted on patients with resectable pancreatic cancer, but that this may change in the future. Many pancreatic cancer cases are metastatic, have a high rate of recurrence, and many patients die within a year of diagnosis. However, there is no confirmatory data that currently suggests that neoadjuvant therapy is superior to adjuvant alone. Furthermore, protocols relating to the length of treatment prior to surgery do not exist. Future trials aim to provide resolutions to these issues, which will allow for neoadjuvant chemotherapy. This interview took place at the ESMO World Congress on Gastrointestinal Cancer (WCGIC) 2023 in Barcelona, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.